VANCOUVER, British Columbia, July 6, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to announce that it has appointed Dr. Lola Maksumova, MD, Ph.D. as Senior Vice President and Chief Operating Officer.
Dr. Maksumova was previously Vice President of Drug Development with Pacific Therapeutics, a pharmaceutical company focused on liver and pulmonary fibrosis. In that position she was responsible for all aspects of drug development, managing the company relationship with the third party contract research organizations and FDA.
"We welcome Dr. Maksumova joining our company and with this addition of a highly experienced drug developer, our programs should go through development more effectively and faster," said Dr. Hassan Salari, Chairman & CEO of Global Health Ventures.
About Sublingual Technology
The Company's drug formulation is designed to enhance the delivery of the medical products faster to the body than current oral formulations. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.
About Global Health Ventures (OTCBB:GHLV)
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has developed a new formulation for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with less drug breakdown in the liver or gastrointestinal system, a process that can reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream faster than the oral route of delivery. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include anti-stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.